Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
Alvotech
SIC 2836 · Biological Products (No Diagnostic Substances)
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Alvotech
SIC 2836 · Biological Products (No Diagnostic Substances)
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
Alvotech
SIC 2836 · Biological Products (No Diagnostic Substances)
Support
about
terms
$
ALVO
Alvotech
CIK:
0001898416
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Profit or loss [abstract]
Product and service revenue
$ 276,271
$ 273,472
$ 48,699
License and other revenue
310,050
216,210
42,735
Other income
2,583
2,296
1,948
Cost of product and service revenue
(235,558)
(185,309)
(160,856)
Research and development expenses
(184,193)
(171,312)
(210,827)
General and administrative expenses
(90,946)
(65,713)
(76,559)
Operating profit
78,207
69,644
(354,860)
Share of net loss of joint venture
0
0
(7,153)
Impairment loss on investment in joint venture
0
0
(21,519)
Loss on sale of interest in joint venture
0
(2,970)
0
Effects resulting from business combination
7,977
0
0
Finance income
198,492
80,145
4,823
Finance costs
(149,190)
(303,165)
(267,157)
Exchange rate differences
(16,841)
8,161
(5,183)
Net gain / (loss) on modification and extinguishment of financial liabilities
17,703
(69,378)
0
Non-operating profit / (loss)
58,141
(287,207)
(296,189)
Profit / (loss) before taxes
136,348
(217,563)
(651,049)
Income tax (expense) benefit
(108,429)
(14,301)
99,318
Profit / (loss) for the year
27,919
(231,864)
(551,731)
Item that will be reclassified to profit or loss in subsequent periods:
Exchange rate differences on translation of foreign operations
3,570
(690)
(86)
Total comprehensive profit / (loss)
$ 31,489
$ (232,554)
$ (551,817)
Profit / (loss) per share
Basic profit / (loss) for the period per share (in dollars per share)
$ 0.10
$ (0.87)
$ (2.43)
v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities
Profit / (loss) for the year
$ 27,919
$ (231,864)
$ (551,731)
Adjustments for non-cash items:
Long-term incentive plan expense
0
0
78
Depreciation, amortization and impairment
37,851
31,301
24,210
Impairment of other intangible assets
0
0
1,779
Impairment loss on investment in joint venture
0
0
21,519
Change in allowance for receivables
703
(946)
18,500
Change in inventory reserves
646
(3,483)
8,341
Share-based payments
7,378
7,626
18,033
Loss on disposal of property, plant and equipment
0
0
365
Effects resulting from business combination
(7,977)
0
0
Loss on sale of interest in joint venture
0
2,970
0
Share of net loss of joint venture
0
0
7,153
Finance income
(198,492)
(80,145)
(4,823)
Finance costs
149,190
303,165
267,157
Exchange rate difference
16,841
(8,161)
5,183
Net (gain) / loss on modification and extinguishment of financial liabilities
(17,703)
69,378
0
Income tax expense / (benefit)
108,429
14,301
(99,318)
Operating cash flow before movement in working capital
124,785
104,142
(283,554)
Increase in inventories
(90,129)
(49,973)
(11,304)
Decrease / (increase) in trade receivables
93,182
(119,063)
(8,320)
(Decrease) increase in receivables with related parties
(320)
20
881
Increase in contract assets
(94,947)
(45,192)
(17,393)
Increase in other assets
(4,244)
(7,125)
(802)
Increase / (decrease) in trade and other payables
45,312
(13,695)
31,772
(Decrease) / increase in contract liabilities
(69,334)
(31,446)
35,396
(Decrease) / increase in liabilities with related parties
(2,233)
(7,871)
1,280
Increase / (decrease) in other liabilities
5,074
(14,299)
(5,182)
Cash from (used in) operations
7,146
(184,502)
(257,226)
Interest received
2,387
4,617
3,649
Interest paid
(58,950)
(54,921)
(57,254)
Income tax paid
(780)
(2,037)
(1,354)
Net cash used in operating activities
(50,197)
(236,843)
(312,185)
Cash flows from investing activities
Acquisition of property, plant and equipment
(64,470)
(53,661)
(33,234)
Disposal of property, plant and equipment
0
0
133
Acquisition of intangible assets
(31,659)
(3,339)
(13,239)
Restricted cash in connection with debt extinguishment
0
26,132
0
Net cash outflow on acquisition of subsidiary
(14,036)
0
0
Proceeds from the sale in joint venture
5,950
12,000
0
Net used in investing activities
(104,215)
(18,868)
(46,340)
Cash flows from financing activities
Repayments of borrowings
(25,419)
(749,082)
(99,367)
Repayments of principal portion of lease liabilities
(10,368)
(10,197)
(8,269)
Proceeds from new borrowings
233,482
896,263
278,831
Transaction cost from new borrowings
(5,585)
(4,236)
(9,004)
Gross proceeds from equity offering
82,481
150,451
136,879
Fees from equity offering
(3,759)
(5,812)
(4,141)
Proceeds from warrants
0
4,843
6,390
Stock options exercised
0
76
0
Proceeds from loans from related parties
0
24,500
0
Repayment of loans from related parties
0
(9,500)
0
Net cash generated from financing activities
270,832
297,306
301,319
(Decrease) increase in cash and cash equivalents
116,420
41,595
(57,206)
Cash and cash equivalents at the beginning of the year
51,428
11,157
66,427
Effect of movements in exchange rates on cash held
4,511
(1,324)
1,936
Cash and cash equivalents at the end of the year
$ 172,359
$ 51,428
$ 11,157
v3.26.1
Consolidated Statements of Financial Position - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Non-current assets
Property, plant and equipment
$ 356,398
$ 284,546
Right-of-use assets
138,294
125,198
Goodwill
12,835
11,330
Other intangible assets
81,834
20,621
Contract assets
122,934
22,710
Other long-term assets
8,578
3,615
Deferred tax assets
192,211
298,360
Total non-current assets
913,084
766,380
Current assets
Inventories
220,054
127,889
Trade receivables
69,740
160,217
Contract assets
64,440
67,304
Other current assets
46,984
48,064
Receivables from related parties
438
118
Cash and cash equivalents
172,359
51,428
Total current assets
574,015
455,020
Total assets
1,487,099
1,221,400
Equity
Share capital
2,929
2,826
Share premium
2,105,691
2,007,058
Other reserves
15,331
17,272
Translation reserve
1,352
(2,218)
Accumulated deficit
(2,409,790)
(2,437,709)
Total equity
(284,487)
(412,771)
Non-current liabilities
Borrowings
1,262,147
1,035,882
Derivative financial liabilities
53,994
210,224
Lease liabilities
137,999
112,137
Contract liabilities
5,500
80,721
Deferred tax liability
7,868
1,811
Total non-current liabilities
1,467,508
1,440,775
Current liabilities
Trade and other payables
126,124
67,126
Lease liabilities
12,078
9,515
Current maturities of borrowings
36,921
32,702
Liabilities to related parties
3,325
8,465
Contract liabilities
30,364
15,980
Taxes payable
1,041
204
Other current liabilities
94,225
59,404
Total current liabilities
304,078
193,396
Total liabilities
1,771,586
1,634,171
Total equity and liabilities
$ 1,487,099
$ 1,221,400